In short
A new clinical trial is underway to assess the effectiveness and safety of THE-630, an oral medication designed to treat advanced gastrointestinal stromal tumors (GIST). This study aims to determine the optimal dosage and evaluate the drug's ability to combat GIST in patients who have not responded well to previous treatments. The trial consists of two phases: a dose escalation phase to establish safety and appropriate dosing, followed by an expansion phase to further examine the drug's effectiveness in different patient groups.
At a glance
- Drug Name
- THE-630
- Drug Type
- Oral KIT tyrosine kinase inhibitor
- Target Condition
- Advanced Gastrointestinal Stromal Tumors (GIST)
- Study Design
- Phase 1/2 clinical trial
- Study Phases
- Dose escalation (Phase 1) and Expansion (Phase 2)
- Primary Objectives
- Determine safety profile, optimal dosage, and efficacy
- Key Measurements
- Adverse events, dose-limiting toxicities, objective response rate
- Patient Population
- GIST patients with disease progression or intolerance to previous treatments
- Treatment Duration
- Up to 24 months
- Administration
- Once daily, continuous oral regimen
What is THE-630?
THE-630 is a new drug being tested for the treatment of gastrointestinal stromal tumors (GIST). It is an oral medication, which means it can be taken by mouth, typically once daily. THE-630 belongs to a class of drugs called KIT tyrosine kinase inhibitors. These drugs work by blocking specific proteins that are involved in the growth and spread of cancer cells.
Target Conditions
THE-630 is primarily being studied for the treatment of: Gastrointestinal Stromal Tumors (GIST): These are rare tumors that occur in the digestive tract, most commonly in the stomach or small intestine. Advanced or metastatic GIST: This refers to GIST that has spread to other parts of the body or cannot be surgically removed. Additionally, the study includes patients with other related conditions such as: Connective tissue neoplasms Soft tissue neoplasms Gastrointestinal neoplasms Digestive system neoplasms These terms all refer to various types of tumors or cancerous growths in the digestive system or surrounding tissues.
How THE-630 Works
THE-630 is a KIT tyrosine kinase inhibitor. To understand how it works: KIT is a protein found on the surface of certain cells, including some cancer cells. In many cases of GIST, the KIT protein is abnormally active, causing uncontrolled cell growth. THE-630 works by blocking (or inhibiting) the activity of the KIT protein. By doing this, it aims to slow down or stop the growth of cancer cells. This targeted approach is designed to attack cancer cells while potentially causing less harm to normal cells compared to traditional chemotherapy.
Clinical Trial Design
The clinical trial for THE-630 is designed in two phases: Phase 1 (Dose Escalation): This phase aims to: Determine the safety profile of THE-630 Identify any dose-limiting toxicities (side effects that prevent increasing the dose) Establish the maximum tolerated dose (MTD) Determine the recommended Phase 2 dose (RP2D) Phase 2 (Expansion): This phase will: Further assess safety and tolerability Evaluate the anti-tumor activity of THE-630 in different GIST patient populations The trial includes patients who have already tried other treatments for GIST and either didn't respond well or couldn't tolerate them.
Safety and Efficacy Assessment
The trial will assess THE-630's safety and effectiveness through various measures: Safety: Monitoring for adverse events (side effects) using standardized criteria Efficacy: Measuring how well the drug works against the tumor, including: Objective Response Rate (ORR): The proportion of patients whose tumors shrink or disappear Duration of Response (DOR): How long the tumor response lasts Progression-Free Survival (PFS): How long patients live without their cancer getting worse Overall Survival (OS): How long patients live overall These assessments will help determine if THE-630 is safe and effective for treating GIST.
Pharmacokinetics
The trial will also study how THE-630 behaves in the body, known as pharmacokinetics. This includes measuring: Cmax: The maximum concentration of the drug in the blood Tmax: The time it takes to reach the maximum concentration AUC: The total exposure to the drug over time These measurements will be taken for both THE-630 and its active metabolite (a substance produced when the body processes the drug). Understanding these factors helps determine the optimal dosing schedule for the medication.
Patient Groups
The trial includes different groups of GIST patients based on their previous treatments: 5th Line or Later: Patients who have tried at least four other treatments, including imatinib, sunitinib, regorafenib, and ripretinib. 3rd-4th Line: Patients who have tried imatinib, sunitinib, and up to one additional therapy. 2nd Line: Patients who have only tried imatinib and haven't received any other systemic therapy for advanced GIST. This approach allows researchers to evaluate how effective THE-630 is for patients at different stages of treatment.